Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Novo Nordisk's Sponsorship Deals With UK Pharmacies Linked To Weight-Loss Drugs Raise Ethical Concerns
08:41am, Tuesday, 07'th Jan 2025
Novo Nordisk A/S NVO, the Danish pharmaceutical giant behind weight-loss drugs Wegovy and Saxenda, is facing scrutiny over its sponsorship deals with U.K. pharmacies.
GLP-1 makers could be under pressure in 2025
07:29pm, Monday, 06'th Jan 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk what is next for the obesity drug makers in 2025.
Novo Nordisk upgraded to Market Perform from Underperform at Bernstein
11:52am, Monday, 06'th Jan 2025
Bernstein upgraded Novo Nordisk to Market Perform from Underperform.
Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential
09:00am, Monday, 06'th Jan 2025
Tyrzepatide seems more effective than semaglutide, but the market for slimming drugs is quite large for both. Both companies have a dominant position in their industry and a solid financial position,
Is Novo Nordisk an Undervalued Stock to Buy Now?
04:30am, Monday, 06'th Jan 2025
Novo Nordisk (NVO 0.15%) has sparked investor interest primarily because of its weight loss treatments.
What's Going on With Novo Nordisk Stock?
05:23am, Sunday, 05'th Jan 2025
Novo Nordisk (NVO 0.15%) has found phenomenal success in treating patients with obesity and diabetes.
Better Buy: Novo Nordisk vs. AstraZeneca
05:42am, Saturday, 04'th Jan 2025
Novo Nordisk (NVO 0.15%) and AstraZeneca (AZN 0.56%) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn't kno
Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz
12:06pm, Friday, 03'rd Jan 2025
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year
Novo Resources to Trade on the OTCQB Market
12:20pm, Thursday, 02'nd Jan 2025
VANCOUVER, British Columbia, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Novo Resources Corp. (TSX: NVO) (ASX: NVO) (OTCQB: NSRPF) announces that it has transitioned its trading platform from the OTCQX to the O
Should You Buy the Dip in Novo Nordisk Stock Right Now?
08:30am, Thursday, 02'nd Jan 2025
The biggest talking point in the pharmaceutical industry at the moment revolves around treatments known as glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists are used to treat diabetes and chron
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
10:51am, Wednesday, 01'st Jan 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
10:25am, Wednesday, 01'st Jan 2025
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novo Nordisk: Be Greedy When Others Are Fearful
03:11am, Wednesday, 01'st Jan 2025
Novo Nordisk should deliver a 24% CAGR over two years, driven by robust obesity drug market growth and improved operational performance, with an intrinsic value implying a 29% safety margin. Despite c
Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
09:01am, Tuesday, 31'st Dec 2024
With only one trading day left in 2024, the S&P 500 Index is up approximately 23%. However, as investors look back on the year, they'll see a textbook example of why the stock market is a poor proxy f
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
06:50pm, Monday, 30'th Dec 2024
In the most recent trading session, Novo Nordisk (NVO) closed at $85.73, indicating a -1.88% shift from the previous trading day.
